14639-9 |
carBAMazepine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
carBAMazepine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14639-9 |
|
|
|
|
Both |
|
|
|
0 |
carBAMazepine SerPl-sCnc |
|
|
|
Y |
|
Carbamazapine; Carbamezapine; Carbazepine; CRBM; DRUG/TOXICOLOGY; Drugs; Epitol; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tegretol; Teril |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
1464-7 |
Epinephrine^pre 300 ug cloNIDine PO |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
EPINEPHrine [Mass/volume] in Plasma --pre 300 ug cloNIDine PO |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
1464-7 |
|
|
|
|
Observation |
|
|
|
0 |
Epineph pre 300 ug CLN PO Plas-mCnc |
|
|
|
Y |
|
Adrenalin; Adrenaline; Adreneline; Before; Catapres; CHEMISTRY.CHALLENGE TESTING; E; Epi; Epin; Epinep; Epineph; Epinphrine; Eppi; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; pre 300 ug CLN PO; QNT; Quan; Quant; Quantitative; Random |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
14640-7 |
Carbon dioxide |
SCnc |
Dial fld |
Pt |
Qn |
|
|
ACTIVE |
Carbon dioxide, total [Moles/volume] in Dialysis fluid |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
14640-7 |
|
|
|
|
Both |
|
|
|
0 |
CO2 Dial fld-sCnc |
|
|
|
Y |
|
Carbonic anhydride; cCO2; Chemistry; CO2; CO2 TOTAL; CO2CT; ctCO2; Diaf; Dialysate; Dialysis fluid; Kidney; Level; Nephrology; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; Substance Concentration; tCO2 |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
14641-5 |
Carbonate |
PrThr |
Calculus |
Pt |
Ord |
|
|
ACTIVE |
Carbonate [Presence] in Stone |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14641-5 |
|
|
|
|
Both |
|
|
|
0 |
Carbonate Stone Ql |
|
|
|
|
|
Calc; Calculi; Carb; Carbonic acid; Chemistry; Gastro; Gastroenterology; GI; Kidney; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; Stn; Stone; Stones |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14642-3 |
Carotene |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Carotene [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14642-3 |
|
|
|
|
Both |
|
|
|
0 |
Carotene SerPl-sCnc |
|
|
|
Y |
|
Beta carotene; Chemistry; Level; Pl; Plasma; Plsm; Point in time; Pro vitamin A; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
Release 2.70: SYSTEM: Updated System from "Ser" as this test can be run on both serum and plasma.; |
0 |
14643-1 |
Catecholamines.free |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Catecholamines Free [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/24 H |
|
|
|
|
|
|
CHEM |
|
14643-1 |
|
|
|
|
Both |
|
|
|
0 |
FCA 24h Ur-sRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; Cate; Catec; Catech; Catechol; Catecholamine; Catecholamines.total; Catechols; Chemistry; Epinephrine+norepinephrine+dopamine; FCA; FR; Non-protein bound; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/(24.h) |
|
|
|
0 |
14644-9 |
chlorproMAZINE |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
chlorproMAZINE [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14644-9 |
|
|
|
|
Both |
|
|
|
0 |
chlorproMAZINE Gast Ql |
|
|
|
|
|
Chlopromazine; Chlorpromaz; DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Thorazine |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14645-6 |
chlorproMAZINE |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
chlorproMAZINE [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14645-6 |
|
|
|
|
Both |
|
|
|
0 |
chlorproMAZINE SerPl-sCnc |
|
|
|
Y |
|
Chlopromazine; Chlorpromaz; DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Thorazine |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14646-4 |
Cholesterol.in HDL |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in HDL [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
14646-4 |
|
|
|
|
Both |
|
|
|
0 |
HDLc SerPl-sCnc |
|
|
|
Y |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; HDLc; HDL-C; Heart Disease; High density lipoprotein cholesterols; Level; Lipid; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; TCHHDL |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
14647-2 |
Cholesterol |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
14647-2 |
|
|
|
|
Both |
|
|
|
0 |
Cholest SerPl-sCnc |
|
|
|
Y |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; Level; Lipid; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
14648-0 |
Chylomicrons |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Chylomicrons [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
14648-0 |
|
|
|
|
Both |
|
|
|
0 |
Chylo SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Chylomicron; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; ULDL; Ultra low density lipoproteins |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
14649-8 |
Cimetidine |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Cimetidine [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14649-8 |
|
|
|
|
Both |
|
|
|
0 |
Cimetidine Gast Ql |
|
|
|
|
|
CIMJ; DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tagamet; Tagj |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
1465-4 |
EPINEPHrine^supine |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
EPINEPHrine [Mass/volume] in Plasma --supine |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
1465-4 |
|
|
|
|
Both |
|
|
|
0 |
Epineph sup Plas-mCnc |
|
|
|
Y |
|
Adrenalin; Adrenaline; Adreneline; CHEMISTRY.CHALLENGE TESTING; E; Epi; Epin; Epinep; Epineph; Epinphrine; Eppi; Level; Lying; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
14650-6 |
Citrate |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Citrate [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/24 H |
|
|
|
|
|
|
CHEM |
|
14650-6 |
|
|
|
|
Both |
|
|
|
0 |
Citrate 24h Ur-sRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; Chemistry; Citric acid; Kidney; Nephrology; QNT; Quan; Quant; Quantitative; Renal; sRate; Substance Rate; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/(24.h) |
|
|
|
0 |
14651-4 |
cloBAZam |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
cloBAZam [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14651-4 |
|
|
|
|
Both |
|
|
|
0 |
cloBAZam SerPl-sCnc |
|
|
|
Y |
|
Clarmyl; Clopax; DRUG/TOXICOLOGY; Drugs; Frisium; Level; Noiafren; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Sederlona; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Urbadan; Urbanol; Urbanyl |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14652-2 |
clomiPRAMINE |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
clomiPRAMINE [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14652-2 |
|
|
|
|
Both |
|
|
|
0 |
clomiPRAMINE SerPl-sCnc |
|
|
|
Y |
|
Anafranil; Anofranil; Clom; Clomip; DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14653-0 |
clomiPRAMINE |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
clomiPRAMINE [Moles/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14653-0 |
|
|
|
|
Both |
|
|
|
0 |
clomiPRAMINE Ur-sCnc |
|
|
|
Y |
|
Anafranil; Anofranil; Clom; Clomip; DRUG/TOXICOLOGY; Drugs; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.42 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14654-8 |
clomiPRAMINE+Norclomipramine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
clomiPRAMINE+Norclomipramine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14654-8 |
|
|
|
|
Observation |
|
|
|
0 |
clomiPRAMINE+Nor SerPl-sCnc |
|
|
|
Y |
|
Anafranil; Anofranil; Clom; Clomip; Clomipramine metabolite; Desmeth; Desmethylclomip; Desmethylclomipramine; DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.69 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
Release 2.69: COMPONENT: Added TALLMAN lettering; |
0 |
14655-5 |
clonazePAM |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
clonazePAM [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14655-5 |
|
|
|
|
Both |
|
|
|
0 |
clonazePAM SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Klonopin; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14656-3 |
cloZAPine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
cloZAPine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14656-3 |
|
|
|
|
Both |
|
|
|
0 |
cloZAPine SerPl-sCnc |
|
|
|
Y |
|
Clozaril; DRUG/TOXICOLOGY; Drugs; FazaClo; Leponex; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14657-1 |
Clozapine+Norclozapine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
cloZAPine+Norclozapine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14657-1 |
|
|
|
|
Both |
|
|
|
0 |
cloZAPine+Nor SerPl-sCnc |
|
|
|
Y |
|
Clozapine metabolite; Clozaril; Desmethylclozapine; DRUG/TOXICOLOGY; Drugs; FazaClo; Leponex; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14658-9 |
Cold agglutinin |
Titr |
Ser/Plas |
Pt |
SemiQn |
|
|
ACTIVE |
Cold agglutinin [Titer] in Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
14658-9 |
|
|
|
|
Both |
|
|
|
0 |
CA Titr SerPl |
|
|
|
Y |
|
Agglut; Agglutination; Agglutinins; Agglutins; AGT; CA; Cold agglutinin titration; Dilution factor; Dilution Factor (Titer); Pl; Plasma; Plsm; Point in time; Random; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
14659-7 |
Collection duration |
Time |
Urine |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Collection duration of Urine |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
14659-7 |
|
|
|
|
|
|
|
|
0 |
Deprecated Collect Duration Ur Qn |
|
|
|
|
|
Coll; Collect; Collect duration; Collected; Durat; Point in time; QNT; Quan; Quant; Quantitative; Random; SPEC; UA; UR; Urn |
2.36 |
1.0k |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
1466-2 |
Follitropin^1.5H post 100 g lutropin IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Follitropin [Mass/volume] in Serum or Plasma --1.5 hours post 100 g lutropin IV |
|
DEL |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1466-2 |
|
|
|
|
Observation |
|
|
|
0 |
Deprecated FSH 1.5H p 100 g LH IV SerPl |
|
|
|
Y |
|
1 1/2 hours; 1 1/2 HR; 1.5h p 100 g LH IV; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; ICSH; Interstitial cell-stimulating hormone; Interstitual cell stimulating hormone; Leutinizing hormone; Level; LH; Luteinizing hormone; Lutenin; Lutenizing hormone; Mass concentration; Ovulation test; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.32 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
14660-5 |
Observation |
Color |
Periton fld |
Pt |
Nom |
|
|
ACTIVE |
Color of Peritoneal fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
14660-5 |
|
|
|
|
Observation |
|
|
|
0 |
Color Prt |
|
|
|
|
|
Ascites; Ascitic fluid; Ascitis; Nominal; Peritoneal fluid; Point in time; Prt; Random; SPEC |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |